A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Merck Sharp & Dohme LLC
Gilead Sciences
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Sun Yat-sen University
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Hoffmann-La Roche
Gilead Sciences
Merck Sharp & Dohme LLC
G1 Therapeutics, Inc.
SynCore Biotechnology Co., Ltd.
Fudan University
Merck Sharp & Dohme LLC
Fudan University
Sanofi